Investigation of Potential Action Concerning Investors of AbbVie Inc. (ABBV)
Kessler Topaz Meltzer & Check, LLP is investigating a potential action on behalf of purchasers of AbbVie Inc. (ABBV) (“AbbVie” or the “Company”) securities between October 27, 2017 and September 18, 2018.
About AbbVie Inc.
AbbVie discovers, develops, manufactures, and sells pharmaceutical products worldwide.
Alleged Wrongful Conduct
Kessler Topaz Meltzer & Check, LLP is investigating whether the AbbVie made false and misleading statements related to adverse information regarding its business and prospects and specifically, whether AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics.
If you purchased shares of AbbVie Inc. (ABBV) securities between October 27, 2017 and September 18, 2018, and would like to learn more about our investigation, please fill out our online form or contact us today at 888-299-7706 or via email at info@ktmc.com.